Back to News
Mar 10, 2026 8:00 AM

Earnings Scheduled For March 10, 2026

Companies Reporting Before The Bell

• Ultralife (NASDAQ:ULBI) is likely to report quarterly earnings at $0.27 per share on revenue of $57.00 million.

• Inspired Entertainment (NASDAQ:INSE) is estimated to report quarterly earnings at $0.22 per share on revenue of $76.75 million.

• Willis Lease Finance (NASDAQ:WLFC) is expected to report quarterly earnings at $3.38 per share on revenue of $149.00 million.

• KVH Industries (NASDAQ:KVHI) is expected to report quarterly earnings at $0.02 per share on revenue of $29.34 million.

• Legend Biotech (NASDAQ:LEGN) is expected to report quarterly loss at $0.18 per share on revenue of $306.03 million.

• Kohl's (NYSE:KSS) is projected to report quarterly earnings at $0.85 per share on revenue of $5.14 billion.

• Apyx Medical (NASDAQ:APYX) is projected to report quarterly loss at $0.06 per share on revenue of $19.13 million.

• United Natural Foods (NYSE:UNFI) is likely to report quarterly earnings at $0.51 per share on revenue of $8.12 billion.

• Custom Truck One Source (NYSE:CTOS) is projected to report quarterly earnings at $0.07 per share on revenue of $583.52 million.

• NIO (NYSE:NIO) is likely to report quarterly loss at $0.05 per share on revenue of $4.61 billion.

• BioNTech (NASDAQ:BNTX) is likely to report quarterly loss at $0.47 per share on revenue of $889.48 million.

• Uranium Energy (AMEX:UEC) is likely to report quarterly loss at $0.03 per share on revenue of $5.00 million.

• Esperion Therapeutics (NASDAQ:ESPR) is likely to report quarterly earnings at $0.26 per share on revenue of $163.90 million.

• Stagwell (NASDAQ:STGW) is likely to report quarterly earnings at $0.26 per share on revenue of $802.12 million.

• Exagen (NASDAQ:XGN) is estimated to report quarterly loss at $0.20 per share on revenue of $16.49 million.

• ABM Indus (NYSE:ABM) is projected to report quarterly earnings at $0.87 per share on revenue of $2.20 billion.

• Optical Cable (NASDAQ:OCC) is projected to report earnings for its first quarter.

• ADC Therapeutics (NYSE: